Image by Doug Wallick via Flickr Investors are finally realizing the potential turnaround at Boston Scientific. Stock is frequently on the Most Active List and the volume is monstrous. Traditional technical analysis interprets the chart as breakout on high volume and generates a strong buy signal at this point. Our
On March 15,2010 when Boston Scientific’s defibrillators were taken off the market, the Wall Street uniformly issued downgrades. Goldman Sachs downgraded to Conviction Sell.: JP Morgan said sell, Barron’s urged investors to sell and the sell chorus chimed throughout the Wall Street. More specifically, several Gurus pronounced that the products
Typically we refrain from posting on this blog the information that is easily available elsewhere. In view of us taking long position on BSX immediately after seven broker downgrades and the importance of this FDA decision, we are making an exception. Here is the reason for Boston Scientific going up
Noble Financial’s checks at Boston Scientific indicate ICD’s and CRT-Ds could return back to the market in 5 days versus some market expectations of months. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD
In spite of a negative article in Barron’s Online and two new broker downgrades, we have 12.5% gain at $7.10. This illustrates the power of ZYX Change Method. ZYX Change Method calls for protecting the gains. We scaled in 20% of the full position. Per the trade methodology of ZYX
In ZYX Change Method, every trade must pass through six screens. In the first Change Screen, we are looking for macro changes. In this case, our long time readers know that we have been negative on medical devices industry because we anticipate going forward macro environment will not be conducive
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized
$BSX is down substantially on FDA issues and competitors $MDT and $STJ have spiked up. These are minor paperwork issues and will not have a long term impact. Scale in on $BSX on dips. Scale in on $MDT and $STJ on spikes. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE
We have been short on $MDT (Medtronics) with the first scale in at $36.20 and more aggressive entry at $38.00. $BSX earnings show weakness in both stents and implantable cardiac devices. Going forward guidance for US is quite a bit lower than expected. This confirms our thesis and we will